Dr Rahim Kanji

Sub-specialties: Cardiology, Heart Failure, Palpitations, Arrhythmias, Hypertension, Familial Hypercholesterolaemia, Chest Pain, angina.

Overview

02036532005

Overview

Dr Rahim Kanji is an outstanding Consultant Cardiologist, working at OneWelbeck, the Chelsea and Westminster NHS Foundation Trust, and the Hammersmith Hospital, part of the Imperial College Healthcare NHS Trust.

About Dr Rahim Kanji

Dr Rahim Kanji provides excellent general cardiology care, treating patients with shortness of breath (owing to heart failure, valvular and structural abnormalities), palpitations (owing to arrhythmia), hypertension, hypercholesterolaemia and chest pain (owing to heart attacks and angina).

In fact, for the latter, Dr Kanji is an expert, and investigates such patients with non-invasive tests, as well as invasive angiography, and treats with balloons and stents (angioplasty) as required. During this, he uses the latest technologies and best equipment, including intravascular imaging, ensuring the best possible, tailored treatment, minimising the risk of stent failure and further heart attacks.

It is this fantastic care, and the care delivered by his colleagues which has resulted in the Chelsea and Westminster Hospital NHS Foundation Trust having the lowest age-standardised mortality rate in England.

At the Hammersmith Hospital, Dr Kanji is mainly focused on the treatment of patients with severe heart attacks, where he performs emergency lifesaving angioplasty.

Dr Kanji also spends a lot of his time and effort delivering talks and education to GPs (as well as cardiology trainees) as he recognises that the majority of cardiac care is provided by GPs in the community, and it is his passion to ensure all patients, including those he is not directly involved with, are in receipt of the best, latest care.

His delivery of outstanding care is only possible thanks to his world-class training in prestigious institutions and of course hard work! He obtained a BSc (in Endocrinology) and a medical degree from Imperial College London where he graduated with distinction. He underwent post-graduate medical training, and thereafter cardiology specialist training in the highly competitive and prestigious London - Imperial deanery, before undertaking a PhD in the risk stratification of patients with heart attacks and aortic stenosis, also awarded by Imperial College London (National Heart and Lung Institute). In fact, thanks to his research, he is considered an expert in anti-platelet therapy and the management of patients with thrombosis (heart attacks), and has published his work in high-impact factor journals.

He is also a pioneer in the virtual wards and virtual hospital space. He is in fact the lead for the chest pain virtual ward at the Chelsea and Westminster Hospital NHS Trust, where he has extensive experience, and managed the largest cohort of patients in the UK. Watch Dr Kanji talk about this in a live SKY news interview.

Dr Kanji would be honoured and privileged to see you at OneWelbeck, and is fully committed to treating, and improving your quality of life.

Areas of Expertise

Dr Rahim Kanji treats a range of conditions including:

Heart failure
Valvular and structural abnormalities
Palpitations
Arrhythmias
Hypertension
Hypercholesterolaemia
Chest pain
Heart attacks
Angina

He performs a range of investigations and treatments including:

Invasive angiography
Angioplasty

Additional Information

Dr Rahim Kanji has featured in the following coverage:

75th birthday of the NHS - live interview on SKY news discussing the challenges in the NHS, and how the virtual wards, for which he is a pioneer, can help to improve cost effectiveness and outcomes.

Research Highlights

Dr Kanji has several publications in peer-reviewed journals, and actively speaks at national and international conferences, including Diabetes Professional Care, Cardio Renal Metabolic UK Summit, EuroThrombosis EuroVessels and British Society for Haemostasis and Thrombosis.

Publications include:

Kanji R, Gue YX, Memtsas V, Spencer NH, Gorog DA. Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2023 May 16;81(19):1918-1932. doi: 10.1016/j.jacc.2023.03.388. PMID: 37164525.

https://pubmed.ncbi.nlm.nih.gov/37164525/

Kanji R, Gue YX, Farag MF, Spencer NH, Mutch NJ, Gorog DA. Determinants of Endogenous Fibrinolysis in Whole Blood Under High Shear in Patients With Myocardial Infarction. JACC Basic Transl Sci. 2022 Aug 24;7(11):1069-1082. doi: 10.1016/j.jacbts.2022.05.007. PMID: 36687271; PMCID: PMC9849272.

https://pubmed.ncbi.nlm.nih.gov/36687271/

Kanji R, Leader J, Memtsas V, Gorog DA. Measuring Thrombus Stability at High Shear, Together With Thrombus Formation and Endogenous Fibrinolysis: First Experience Using the Global Thrombosis Test 3 (GTT-3). Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231181917. doi: 10.1177/10760296231181917. PMID: 37551011; PMCID: PMC10411283.

https://pubmed.ncbi.nlm.nih.gov/37551011/

Kanji R, Vandenbriele C, Arachchillage DRJ, Price S, Gorog DA. Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation. Thromb Haemost. 2022 Apr;122(4):480-491. doi: 10.1055/a-1508-8230. Epub 2021 Jun 21. PMID: 33984868.

https://pubmed.ncbi.nlm.nih.gov/33984868/

Kanji R, Gue YX, Memtsas V, Gorog DA. Fibrinolysis in Platelet Thrombi. Int J Mol Sci. 2021 May 12;22(10):5135. doi: 10.3390/ijms22105135. PMID: 34066261; PMCID: PMC8152010.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152010/

Kanji R, Jenner WJ, Mirsadraee S, Gue YX, Price S, Prasad S, Gorog DA. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review. J Thromb Thrombolysis. 2021 Apr;51(3):595-607. doi: 10.1007/s11239-021-02394-7. Epub 2021 Feb 14. PMID: 33586113; PMCID: PMC7882250.

https://pubmed.ncbi.nlm.nih.gov/33586113/

Kanji, R., Mirsadraee, S., Prasad, S., Gue, Y. X., Panoulas, V., & Gorog, D. A. Thrombosis Risk with Transcatheter Aortic Valve Replacement. Structural Heart. 2020 4(5), 349–359.

https://doi.org/10.1080/24748706.2020.1797256

Kanji R, Kubica J, Navarese EP, Gorog DA. Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment. Eur J Clin Invest. 2021 Apr;51(4):e13471. doi: 10.1111/eci.13471. Epub 2020 Dec 16. PMID: 33296082.

https://pubmed.ncbi.nlm.nih.gov/33296082/

Gue YX, Memtsas V, Kanji R, Wellsted DM, Busby A, Smith M, Vilar E, Ryding A, Arachchillage DJ, Gorog DA. Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study. Thromb Res. 2024 Apr;236:144-154. doi: 10.1016/j.thromres.2024.02.030. Epub 2024 Mar 3. PMID: 38447421.

https://pubmed.ncbi.nlm.nih.gov/38447421/

Leader JH, Kanji R, Gorog DA. Spontaneous reperfusion in STEMI: Its mechanisms and possible modulation. Kardiol Pol. 2024;82(4):363-374. doi: 10.33963/v.phj.99737. Epub 2024 Mar 17. PMID: 38493469.

https://pubmed.ncbi.nlm.nih.gov/38493469/

Gue YX, Kanji R, Wellsted DM, Srinivasan M, Wyatt S, Gorog DA. Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. J Thromb Thrombolysis. 2020 Feb;49(2):192-198. doi: 10.1007/s11239-019-02014-5. PMID: 31872349; PMCID: PMC6969858.

https://pubmed.ncbi.nlm.nih.gov/31872349/

Gue YX, Kanji R, Gati S, Gorog DA. MI with Non-obstructive Coronary Artery Presenting with STEMI: A Review of Incidence, Aetiology, Assessment and Treatment. Eur Cardiol. 2020 Apr 30;15:e20. doi: 10.15420/ecr.2019.13. PMID: 32419851; PMCID: PMC7215489.

https://pubmed.ncbi.nlm.nih.gov/32419851/

Kanji R, Dinarvand D, GueYX, Gorog DA, Myocardial infarction with non-obstructive coronary arteries in young women presenting with ST-segment elevation myocardial infarction: a case series. Medical Research Journal 2020;5(1):55-60. doi: 10.5603/MRJ.a2020.0006

https://journals.viamedica.pl/medical_research_journal/article/view/67839

Gue YX, Sayers M, Whitby BT, Kanji R, Adatia K, Smith R, Davies WR, Perperoglou A, Potpara TS, Lip GYH, Gorog DA. Usefulness of the NULL-PLEASE Score to Predict Survival in Out-of-Hospital Cardiac Arrest. Am J Med. 2020 Nov;133(11):1328-1335. doi: 10.1016/j.amjmed.2020.03.046. Epub 2020 May 7. PMID: 32387318.

https://pubmed.ncbi.nlm.nih.gov/32387318/

Gue YX, Adatia K, Kanji R, Potpara T, Lip GYH, Gorog DA. Out-of-hospital cardiac arrest: A systematic review of current risk scores to predict survival. Am Heart J. 2021 Apr;234:31-41. doi: 10.1016/j.ahj.2020.12.011. Epub 2020 Dec 31. PMID: 33387469.

https://pubmed.ncbi.nlm.nih.gov/33387469/

Gue YX, Kanji R, Markides V, Gorog DA. Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19. Am J Cardiol. 2020 Sep 1;130:161-162. doi: 10.1016/j.amjcard.2020.06.002. Epub 2020 Jun 9. PMID: 32636018; PMCID: PMC7282749.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282749/

Gue YX, Tennyson M, Gao J, Ren S, Kanji R, Gorog DA. Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19. Sci Rep. 2020 Dec 7;10(1):21379. doi: 10.1038/s41598-020-78505-w. Erratum in: Sci Rep. 2021 Apr 7;11(1):8011. doi: 10.1038/s41598-021-87439-w. PMID: 33288840; PMCID: PMC7721695.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721695/

Barbero U, Kanji R, Cerrato E, Di Summa R, Conrotto F, Kawamoto H, Biondi-Zoccai G, Gili S, Ugo F, Iannaccone M, Gagliardi M, De Benedictis M, Doronzo B, Varbella F, D'Amico M, Moretti C, Colombo A, Escaned J, D'Ascenzo F. Unprotected Left Main Coronary Artery Disease: Outcomes of Treatment With Second-Generation Drug-Eluting Stents - Insight From the FAILS-2 Study. J Invasive Cardiol. 2018 Aug;30(8):283-288. Epub 2018 May 15. PMID: 29760284.

https://pubmed.ncbi.nlm.nih.gov/29760284/

Barbero U, D'Ascenzo F, Campo G, Kleczyński P, Dziewierz A, Menozzi M, Jiménez Díaz VA, Cerrato E, Raposeiras-Roubín S, Ielasi A, Rognoni A, Fineschi M, Kanji R, Jaguszewski MJ, Picchi A, Andò G, Soraci E, Mancone M, Sardella G, Calcagno S, Gallo F, Huczek Z, Krakowian M, Verardi R, Montefusco A, Omedè P, Lococo M, Moretti C, D'Amico M, Rigattieri S, Gaita F, Rinaldi M, Escaned J. Safety of FFR-guided revascularisation deferral in Anatomically prognostiC diseasE (FACE: CARDIOGROUP V STUDY): A prospective multicentre study. Int J Cardiol. 2018 Nov 1;270:107-112. doi: 10.1016/j.ijcard.2018.06.013. Epub 2018 Jun 8. PMID: 29937300.

https://pubmed.ncbi.nlm.nih.gov/29937300/

Kanji R, Gue YX, Dinarvand D, Farag MQ, Gorog DA, Assessment of endogenous fibrinolysis using a point-of-care assay to identify increased cardiovascular risk in patients with diabetes and ACS. European Heart Journal. Volume 41, Issue Supplement_2, November 2020, ehaa946.1540

https://doi.org/10.1093/ehjci/ehaa946.1540

R Kanji, Y.X Gue, D Dinarvand, D.A Gorog, No difference in thrombotic profile of patients with ACS with obstructive CAD and MINOCA. European Heart Journal. Volume 41, Issue Supplement_2, November 2020, ehaa946.1541

https://doi.org/10.1093/ehjci/ehaa946.1541

Major insurers served

If your insurer is not listed, please contact us to confirm your coverage. Please note this does not guarantee coverage or fee assurance. Patients should confirm with their insurer to ensure coverage, check if the doctor is fee-assured, or verify if their policy includes the doctor in question.